This post is from a suggested group
Biosimilars
Biosimilars are biological products that are highly similar to an already approved reference biologic. Because biological medications are produced from living organisms, they are inherently more complex than traditional chemical drugs, requiring a rigorous process to ensure that there are no clinically meaningful differences between the two products.
The approval of these agents is based on extensive analytical studies and clinical trials that demonstrate equivalent safety, purity, and potency. By providing more options for the treatment of conditions such as rheumatoid arthritis and various cancers, these agents play a crucial role in expanding patient access to advanced care.
The manufacturing of a biosimilar involves a high degree of precision, as even small changes in the production process can affect the final structure of the protein. Scientists use sophisticated mapping techniques to compare the molecular "fingerprint" of the biosimilar with the reference product. Once bioequivalence is established, the product can be…